23:57 , Jul 13, 2017 |  BC Week In Review  |  Clinical News

Windtree's Aerosurf misses in Phase IIb for RDS

Windtree Therapeutics Inc. (OTCQB:WINT) reported top-line data from a blinded, international Phase IIb trial in 221 premature infants 28-32 weeks of gestational age with respiratory distress syndrome (RDS) showing that up to 2 repeat doses...
21:31 , Jun 16, 2017 |  BC Week In Review  |  Company News

Windtree grants Lee’s Asian rights to its KL4 surfactant products, including Aerosurf and Surfaxin

Windtree Therapeutics Inc. (OTCQB:WINT) granted Lee’s Pharmaceutical Holdings Ltd. (HKSE:950) exclusive rights to develop and commercialize KL4 surfactant products in China, Taiwan, Thailand and 13 other Asian territories based on Windtree’s KL4 surfactant and aerosolization...
19:52 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Windtree completes enrollment in Phase IIb of Aerosurf to treat RDS in premature infants

Windtree Therapeutics Inc. (OTCQB:WINT) completed enrollment of 221 premature infants 28-32 weeks of gestational age with respiratory distress syndrome (RDS) in a Phase IIb trial of Aerosurf lucinactant. The trial is comparing up to 2...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

Aerosurf lucinactant: Phase IIb started

Discovery Labs began a double-blind, international Phase IIb trial to compare up to 2 repeat doses of 25 or 50 minutes of aerosolized Aerosurf plus nasal continuous positive airway pressure (nCPAP) vs. nCPAP alone in...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

Aerosurf: Completed Phase IIa enrollment

Discovery Labs completed enrollment of 32 premature infants of 29-34 weeks gestational age in an open-label Phase IIa trial comparing 60 and 90 minutes of aerosolized Aerosurf plus nasal continuous positive airway pressure (nCPAP) vs....
07:00 , Jul 27, 2015 |  BC Week In Review  |  Clinical News

Aerosurf: Phase IIa data

Top-line data from an open-label, dose-escalation, U.S. Phase IIa trial in 48 premature infants receiving nasal continuous positive airway pressure (nCPAP) for RDS showed that single doses of 25, 50 and 75 mg/kg inhaled Aerosurf...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Clinical News

Aerosurf: Phase IIa started

Discovery Labs began an open-label Phase IIa trial to compare repeat doses of aerosolized Aerosurf plus nasal continuous positive airway pressure vs. nasal continuous positive airway pressure alone in premature infants 29-34 weeks gestational age....
07:00 , Apr 6, 2015 |  BioCentury  |  Finance

Up, up and acquired

For the first time since 1Q14, none of the biotech market cap segments fell. While the $200-$499 million tier treaded water, all other segments finished in the black, led by the $1-$4.9 billion segment. Large...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Company News

Discovery Laboratories pulmonary news

Discovery Laboratories disclosed in its 2014 financial results that it will restructure to focus on development of Aerosurf aerosolized KL4 surfactant for respiratory diseases, beginning with respiratory distress syndrome (RDS) in premature infants....
08:00 , Nov 18, 2013 |  BC Week In Review  |  Company News

Discovery Laboratories sales and marketing update

Discovery Labs launched Surfaxin lucinactant in the U.S. to prevent respiratory distress syndrome (RDS) in premature infants. The product has a wholesale acquisition price of $860 for an 8.5 mL vial. The recommended dose...